NHS Logo

Hormone Related Cancer Mechanistic and Nanomedicines (Record no. 101335)

MARC details
000 -LEADER
fixed length control field 04004nam a22004935i 4500
001 - CONTROL NUMBER
control field 978-981-19-5558-7
003 - CONTROL NUMBER IDENTIFIER
control field DE-He213
005 - DATE AND TIME OF LATEST TRANSACTION
control field 20240729134304.0
007 - PHYSICAL DESCRIPTION FIXED FIELD--GENERAL INFORMATION
fixed length control field cr nn 008mamaa
008 - FIXED-LENGTH DATA ELEMENTS--GENERAL INFORMATION
fixed length control field 230108s2022 si | s |||| 0|eng d
020 ## - INTERNATIONAL STANDARD BOOK NUMBER
ISBN 9789811955587
-- 978-981-19-5558-7
072 #7 - SUBJECT CATEGORY CODE
Subject category code MJCL
Source bicssc
072 #7 - SUBJECT CATEGORY CODE
Subject category code MED062000
Source bisacsh
072 #7 - SUBJECT CATEGORY CODE
Subject category code MJCL
Source thema
245 10 - TITLE STATEMENT
Title Hormone Related Cancer Mechanistic and Nanomedicines
Subtitle : Challenges and Prospects /
250 ## - EDITION
Edition statement 1st ed. 2022.
264 #1 - PRODUCTION, PUBLICATION, DISTRIBUTION, MANUFACTURE, AND COPYRIGHT NOTICE
Place of production, publication, distribution, manufacture Singapore :
Name of producer, publisher, distributor, manufacturer Springer Nature Singapore :
-- Imprint: Springer,
Date of production, publication, distribution, manufacture, or copyright notice 2022.
300 ## - PHYSICAL DESCRIPTION
Physical description XIV, 347 p. 1 illus.
Other physical details online resource.
336 ## - CONTENT TYPE
Content type term text
Content type code txt
Source rdacontent
337 ## - MEDIA TYPE
Media type term computer
Media type code c
Source rdamedia
338 ## - CARRIER TYPE
Carrier type term online resource
Carrier type code cr
Source rdacarrier
505 0# - CONTENTS
Contents Chapter 1. Conventional Treatment Approaches in Hormonal Cancer Treatment and Challenges -- Chapter 2. Concept of Nanomedicine in Endocrine Hormone Cancer Treatment -- Chapter 3. Progress of Cancer Nanomedicine, Clinical Hurdles and Opportunities -- Chapter 4. Emergence of Nanohybrids in Hormonal Cancer Targeted Therapy -- Chapter 5. Conventional to Nanoscale-Based Carrier System in Management of Ovarian Cancer -- Chapter 6. Pancreatic Cancer Nanoparticles Targeted Therapy via Epidermal Growth Factor Receptor -- Chapter 7. Nanocarriers Based Targeted Therapies for Pancreatic Cancer and Challenges Ahead -- Chapter 8. Pancreatic Cancer Treatment by Using of Theranostics Nanoparticles -- Chapter 9. Nanomedicine Based Combinational Therapy for Breast Cancer -- Chapter 10. Nano-Liposomal System for Breast Cancer Therapy -- Chapter 11. Conventional to Nanotherapeutic Strategies against Triple-Negative Breast Cancer -- Chapter 12. Effect of Thymoquinone and Its Delivery Through Using of Nanomedicine inBenign Prostatic Hyperplasia -- Chapter 13. Concept of Nanotechnology in Management of Neuroendocrine Tumours -- Chapter 14. Neurocognitive Underpinning of Neurological Disorders: The Role of Default Mode Network -- Chapter 15. Neuroendocrine Carcinoma of The Endometrium: Conventional Treatment Approach to Nanomedicine -- Chapter 16. Effective Luteinizing Hormone Drug Delivery by Gold Nanoparticles in Hormonal Cancer Treatment -- Chapter 17. Regulatory Landscapes in Approval of Cancer Vaccines.
520 ## - ABSTRACT
Abstract The nanotheranostics sector provides a very promising strategy for monitoring drug biodistribution and pathology longitudinal processes by integrating the imaging and drug delivery functions in one single nanoformulation, providing vital insights into the identification of tumour and predicting the efficacy of nanomedicine. For its unique properties, which include their small size and biocompatibility and ability to permeate the cellular membrane with carrying drugs, nanomaterials have been used for various biomedical applications. This book covers the progress made in hormone-related cancer and their management by nonmedicinal therapy for targeting the hormone regulated cancer with their clinical progress and clinical hurdles.
650 #0 - SUBJECT HEADINGS
Subject term Oncology.
9 (RLIN) 13364
650 #0 - SUBJECT HEADINGS
Subject term Hormones.
650 #0 - SUBJECT HEADINGS
Subject term Cancer.
650 14 - SUBJECT HEADINGS
Subject term Oncology.
9 (RLIN) 13364
650 24 - SUBJECT HEADINGS
Subject term Hormone.
650 24 - SUBJECT HEADINGS
Subject term Cancers.
700 1# - ADDED PERSONAL NAME
Added personal author Rahman, Mahfoozur.
Relator term editor.
700 1# - ADDED PERSONAL NAME
Added personal author H Almalki, Waleed.
Relator term editor.
700 1# - ADDED PERSONAL NAME
Added personal author Alrobaian, Majed.
Relator term editor.
700 1# - ADDED PERSONAL NAME
Added personal author Beg, Sarwar.
Relator term editor.
700 1# - ADDED PERSONAL NAME
Added personal author Alharbi, Khalid S.
Relator term editor.
710 2# - ADDED CORPORATE NAME
Added corporate author SpringerLink (Online service)
856 ## - ONLINE RESOURCE
Uniform Resource Identifier <a href="#gotoholdings">#gotoholdings</a>
Link text Access resource
245 ## - TITLE STATEMENT
Medium [E-Book]
347 ## - DIGITAL FILE CHARACTERISTICS
File type text file
Encoding format PDF
Source rda
912 ## -
-- ZDB-2-SME
912 ## -
-- ZDB-2-SXM
Holdings
Withdrawn status Lost status Damaged status Not for loan Home library Current library Shelving location Date acquired Source of acquisition Total Checkouts Date last seen Uniform Resource Identifier Price effective from Koha item type
        Hillingdon Hospitals Library Services (Hillingdon Hospitals NHS Foundation) Hillingdon Hospitals Library Services (Hillingdon Hospitals NHS Foundation) Online 02/05/2024 Springer BiomedLifeSc   02/05/2024 https://go.openathens.net/redirector/nhs?url=https://doi.org/10.1007/978-981-19-5558-7 02/05/2024 Electronic book
London Health Libraries Consortium Privacy notice and Membership terms and conditions